Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey
2013 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 15, no 10, 1526-1532 p.Article in journal (Refereed) Published
The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke prevention in atrial fibrillation (AF), particularly into the use of novel oral anticoagulants (NOACs) for stroke prevention, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of NOACs for stroke prevention in AF. There were clear practice differences evident, and also the need for greater adherence to the guidelines, especially since guideline adherent management results in better outcomes in AF.
Place, publisher, year, edition, pages
2013. Vol. 15, no 10, 1526-1532 p.
Atrial fibrillation, Anticoagulation, Guidelines, Warfarin, New oral anticoagulants, Apixaban, Dabigatran, Rivaroxaban, Stroke, EP wire, EHRA survey
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-210195DOI: 10.1093/europace/eut292ISI: 000325180200026OAI: oai:DiVA.org:uu-210195DiVA: diva2:661525
Conducted by the Scientific Initiative Committee, European Heart Rhythm Association2013-11-042013-11-042013-11-04Bibliographically approved